Ibrutinib Fails in High-Risk Early-Stage CLL

Published Date: 29 Aug 2026

Ibrutinib improves event-free survival in certain genetic subgroups of early-stage chronic lymphocytic leukemia but fails to extend overall survival.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Preschoolers With Cancer Have Poor Motor Skills

2.

Significant differences in breast cancer care still exist, but surgeons can change.

3.

Discovery of a new biomarker for early detection of bladder cancer in both dogs and humans

4.

Alternative Medicine for Breast Cancer: Study Raises Concern

5.

A hint regarding aspirin, the connection to colon cancer, the approval of the new Lutathera, artificial intelligence, and electronic records.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot